In vitro evaluation of VIP/PACAP receptors in healthy and diseased human tissues: Clinical implications

Annals of the New York Academy of Sciences

Volumn 921, Issue , 2000, Pages 1-25

  Reubi, J C ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE RECEPTOR; RECEPTOR SUBTYPE; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR;

BREAST; CONFERENCE PAPER; CONTROLLED STUDY; GASTROINTESTINAL MUCOSA; HUMAN; HUMAN TISSUE; IN VITRO STUDY; KIDNEY PARENCHYMA; LEIOMYOMA; LIVER; LYMPHOID TISSUE; LYMPHOMA; MENINGIOMA; PROSTATE; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; TISSUE DISTRIBUTION; TUMOR;

EID: 0034499735     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2000.tb06946.x     Document Type: Conference Paper

References (47)

1. Localisation of endocrine-related tumours with radioiodinated analogue of somatostatin
2. Neuropeptide receptors in health and disease: The molecular basis for in vivo imaging
3. Somatostatin receptor scintigraphy: Its sensitivity compared with that of other imaging methods in detecting primary and metastatic gastrinomas
4. Yttrium-90-labelled somatostatin-analogue for cancer treatment
5. Somatostatin receptor: Scintigraphy and radionuclide therapy
6. In vitro identification of vasoactive intestinal peptide receptors in human tumors: Implications for tumor imaging
7. Somatostatin and vasoactive intestinal peptide receptors in human mesenchymal tumors: In vitro identification
8. Regulatory peptide receptors in human hepatocellular carcinomas
9. Receptor autoradiographic evaluation of cholecystokinin, neurotensin, somatostatin, and vasoactive intestinal peptide receptors in gastro-intestinal adenocarcinoma samples: Where are they really located?
10. Pituitary adenylate-cyclase-activating polypeptide (PACAP) binding sites and PACAP/vasoactive intestinal polypeptide receptor expression in human pituitary adenomas
11. Vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptor subtypes in human tumors and their tissues of origin
12. Absence of somatostatin receptors in human exocrine pancreatic adenocarcinomas
13. Switches in the expression and function of PACAP and VIP receptors during phenotypic interconversion in human neuroblastoma cells
14. Vasoactive intestinal peptide inhibits the growth of hamster pancreatic cancer but not human pancreatic cancer in vivo
15. Vasoactive intestinal peptide (VIP) stimulates in vitro growth of VIP-1 receptor-bearing human pancreatic adenocarcinoma-derived cells
16. Expression of somatostatin receptor subtype 1-5 genes in human pancreatic cancer
17. Immunohistochemical localization of somatostatin receptors sst2A in human tumors
18. International union of pharmacology. XVIII. Nomenclature of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide
19. Development of high affinity selective VIP1 receptor agonists
20. 2 receptor subclass
21. Autoradiographic visualization of the receptor subclasses for vasoactive intestinal polypeptide (VIP) in rat brain
22. Receptors for pituitary adenylate cyclase activating peptides in human pituitary adenomas
23. Localization of receptors for vasoactive intestinal peptide, somatostatin, and substance P in distinct compartments of human lymphoid organs
24. High affinity specific binding of vasoactive intestinal peptide to human circulating T cells, B cells and large granular lymphocytes
25. Perspectives on pituitary adenylate cyclase activating polypeptide (PACAP) in the neuroendocrine, endocrine, and nervous systems
26. Expression of pituitary adenylate cyclase activating polypeptide (PACAP) receptors in human glial cell tumors
27. Pituitary adenylate cyclase activating peptide and its receptors are expressed in human neuroblastomas
28. A critical view of the methods for characterization of the VIP/PACAP receptor subclasses
29. N-terminal splice variants of the type I PACAP receptor: Isolation, characterization and ligand binding/selectivity determinants
30. Two receptors for vasoactive intestinal polypeptide with similar specificity and complementary distributions
31. Vasoactive intestinal peptide-receptor imaging for the localization of intestinal adenocarcinomas and endocrine tumors
32. Maxadilan is a specific agonist and its deleted peptide (M65) is a specific antagonist for PACAP type 1 receptor
33. 99mTc-labeled vasoactive intestinal peptide receptor agonist: Functional studies
34. TC-99M labeled vasoactive intestinal peptide (VIP) analog for imaging tumors in humans
35. 21) VIP: Evaluation of biological activity and localization to breast cancer tumors
36. Cross-competition between vasoactive intestinal peptide and somatostatin for binding to tumor cell membrane receptors
37. The somatostatin receptor (SSTR) subtype 3 acts as an acceptor of vasoactive intestinal peptide (VIP)
38. Inhibition of human neuroblastoma growth by a specific VIP antagonist
39. A vasoactive intestinal peptide antagonist inhibits non-small cell lung cancer growth
40. Breast cancer growth is inhibited by vasoactive intestinal peptide (VIP) hybrid, a synthetic VIP receptor antagonist
41. Pituitary adenylate cyclase activating peptide receptors regulate the growth of non-small cell lung cancer cells
42. Vasoactive intestinal peptide inhibits human small-cell lung cancer proliferation in vitro and in vivo
43. Relevance of somatostatin receptors and other peptide receptors in pathology
44. Modification of VIP intestinal content associated with abnormal nervous myenteric plexus: A biological feature of chronic intestinal obstruction
45. A novel neuropeptide, pituitary adenylate cyclase-activating polypeptide (PACAP), in human intestine: Evidence for reduced content in Hirschsprung's disease
46. Absence of immunoreactive vasoactive intestinal polypeptide in tissue from the lungs of patients with asthma